Genetic engineering and unlimited expansion of induced pluripotent stem cells (iPSCs) make them a stable source of seed cells for the development of generic off-the-shelf cell drugs.

This groundbreaking technology is increasingly recognized as a pivotal innovation in the field of cellular therapy.